Resources
Download this reportLife Sciences Industry
Inside this issue
• How changes in the US healthcare system will affect patients, doctors and businesses
• Drug groups feel price pressure around the globe - -
Content
Focus shifts to the emerging economies
Andrew Jack notes unprecedented diversification in product ranges and markets in face of economic pressures
Chronic diseases: Poor find unhealthy choices are cheaper
Rowenna Davis says risk factors are more prevalent in developing countries
EU legislation: Crossborder care stuck in waiting room
Stanley Pignal on efforts to give patients the right to access health services anywhere in Europe
US healthcare: Reforms get started with small but certain steps
Anna Fifield considers how changes will affect patients, doctors and insurance companies
Pharmaceuticals: Drug groups feel price pressure around the globe
But the larger ones continue to seek to develop new products, says Andrew Jack
UK biotech: Investors grow wary of smallscale drug developers
Medical device companies may now find more favour as a safer investment, says John O’Doherty
Agriculture and food: The genetically modified crop marches on
Types introduced so far have benefited farmers rather than consumers, writes Clive Cookson
Charging schemes: Price hangs on patient outcomes
Andrew Jack finds some drug companies choosing to be paid by results
Regenerative medicine: Possibilities multiply for nerve cell regrowth
Clive Cookson looks at therapies under test to tackle disease and injury of the brain or nervous system
Electronic records: Making slow progress
Across the world, the drive to create electronic medical records is making progress slower than hoped for, while costs are higher, says Nicholas Timmins
